KemPharm, Inc. (NASDAQ:KMPH) Files An 8-K Other Events
Item 8.01 Other Events.
On October 31, 2019, KemPharm, Inc. (the “Company”) provided a commercial update related to APADAZ®, its combination benzhydrocodone and acetaminophen product, which has been licensed to KVK Tech, Inc. (“KVK”) for commercialization. Specifically, KVK has informed the Company that APADAZ and its authorized generic (AG-APADAZ) will be nationally available in November 2019.
About KemPharm, Inc. (NASDAQ:KMPH)
KemPharm, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP). The Company is developing KP201/APAP as an immediate release (IR), a product candidate for the short-term, or no longer than 14 days for the management of acute pain. The Company has designed KP201/APAP with abuse-deterrent properties to address the epidemic of opioid abuse in the United States. The Company also focuses on developing the pipeline of additional prodrug product candidates that targets pain and attention deficit hyperactivity disorder (ADHD). The Company’s products include KP201/IR (APAP-free), KP511/ER, KP415, KP606/IR and KP746.
